Liaoning He Eye Hospital Group (SZSE:301103) Could Be Struggling To Allocate Capital
Liaoning He Eye Hospital Group (SZSE:301103) Could Be Struggling To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Having said that, from a first glance at Liaoning He Eye Hospital Group (SZSE:301103) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look.
如果你在尋找下一款多功能裝袋機時不確定從哪裏開始,那麼你應該留意一些關鍵趨勢。首先,我們想找一個正在成長的 返回 關於已用資本(ROCE),然後除此之外,還不斷增加 基礎 所用資本的比例。這向我們表明,它是一臺複合機器,能夠持續將其收益再投資到業務中併產生更高的回報。話雖如此,乍一看遼寧和眼科醫院集團(SZSE: 301103),我們並不是對回報率的走勢不屑一顧,但讓我們更深入地了解一下。
What Is Return On Capital Employed (ROCE)?
什麼是資本使用回報率(ROCE)?
For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Liaoning He Eye Hospital Group:
對於那些不知道的人來說,ROCE是衡量公司年度稅前利潤(其回報率)的指標,相對於該業務使用的資本。分析師使用這個公式來計算遼寧和眼科醫院集團的利潤:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)
0.04 = CN¥96m ÷ (CN¥2.6b - CN¥202m) (Based on the trailing twelve months to September 2023).
0.04 = 9600萬元人民幣 ÷(26億元人民幣-2.2億元人民幣) (基於截至2023年9月的過去十二個月)。
So, Liaoning He Eye Hospital Group has an ROCE of 4.0%. In absolute terms, that's a low return and it also under-performs the Healthcare industry average of 11%.
因此,遼寧和眼科醫院集團的投資回報率爲4.0%。從絕對值來看,回報率很低,也低於醫療保健行業11%的平均水平。
See our latest analysis for Liaoning He Eye Hospital Group
查看我們對遼寧何氏眼科醫院集團的最新分析
Historical performance is a great place to start when researching a stock so above you can see the gauge for Liaoning He Eye Hospital Group's ROCE against it's prior returns. If you want to delve into the historical earnings, revenue and cash flow of Liaoning He Eye Hospital Group, check out these free graphs here.
歷史表現是研究股票的絕佳起點,因此在上方您可以看到遼寧和眼科醫院集團的投資回報率與先前的回報對比的指標。如果您想深入了解遼寧和眼科醫院集團的歷史收益、收入和現金流,請在此處查看這些免費圖表。
So How Is Liaoning He Eye Hospital Group's ROCE Trending?
那麼遼寧河眼科醫院集團的投資回報率走勢如何?
When we looked at the ROCE trend at Liaoning He Eye Hospital Group, we didn't gain much confidence. Around five years ago the returns on capital were 9.9%, but since then they've fallen to 4.0%. Although, given both revenue and the amount of assets employed in the business have increased, it could suggest the company is investing in growth, and the extra capital has led to a short-term reduction in ROCE. If these investments prove successful, this can bode very well for long term stock performance.
當我們查看遼寧和眼科醫院集團的投資回報率趨勢時,我們並沒有獲得太大的信心。大約五年前,資本回報率爲9.9%,但此後已降至4.0%。儘管考慮到該業務的收入和資產數量都有所增加,但這可能表明該公司正在投資增長,而額外的資本導致了投資回報率的短期下降。如果這些投資被證明是成功的,這對長期股票表現來說可能是個好兆頭。
The Bottom Line On Liaoning He Eye Hospital Group's ROCE
遼寧和眼科醫院集團投資回報率的底線
While returns have fallen for Liaoning He Eye Hospital Group in recent times, we're encouraged to see that sales are growing and that the business is reinvesting in its operations. These growth trends haven't led to growth returns though, since the stock has fallen 30% over the last year. As a result, we'd recommend researching this stock further to uncover what other fundamentals of the business can show us.
儘管近來遼寧和眼科醫院集團的回報率有所下降,但令我們感到鼓舞的是,銷售額正在增長,該業務正在對其運營進行再投資。但是,這些增長趨勢並未帶來增長回報,因爲該股去年下跌了30%。因此,我們建議進一步研究這隻股票,以發現該業務的其他基本面可以向我們展示什麼。
On a final note, we've found 2 warning signs for Liaoning He Eye Hospital Group that we think you should be aware of.
最後,我們發現了遼寧河眼科醫院集團的兩個警告信號,我們認爲你應該注意這些信號。
If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.
如果你想尋找收益豐厚的穩健公司,可以免費查看這份資產負債表良好且股本回報率可觀的公司名單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。